Serum CA 15.3, CEA and ESR were longitudinally determined in 298 patients with breast cancer during postsurgical follow-up and/or therapy. Observation lasted until the death of the patient or at least for three years. With regard to longitudinal serum markers and ESR curves, four different patterns have been identified: pattern I: the markers and ESR stayed at normal levels; pattern II: the markers and ESR decreased from a peak level; pattern III: the markers and ESR fluctuated widely; pattern IV: the markers and ESR increased steadily.
We have looked at overall survival (OS) and relapse-free survival (RFS) versus longitudinal CA 15.3, CEA and ESR patterns. Univariate Cox regression analysis showed that OS and RFS were significantly associated with all four patterns.
ZatońskiW., TyczyńśkiJ.Nowotwory Zlośliwe w Polsce w 1993 roku.Centrum Onkologii-InstytutWarszawa1996.
2.
FoxM.S.On the diagnosis and treatment of breast cancer.JAMA1979; 241: 489–95.
3.
NemotoT., VanaJ., BedvaniR.N., BakerH.W., McGregorF.H., MurphyG.P.Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons.Cancer1980; 45: 2917–25.
4.
GoldieJ.H., ColdmanA.J.The genetic origin of drug resistance in neoplasms: Implication for systemic therapy.Cancer Res1979; 44: 3643–53.
5.
ClarkG.M., SledgeG.W.Jr., OsborneC.K., McGuireW.L.Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.J Clin Oncol1987; 5: 55–61.
6.
MolinaR., ZanonG., FilellaX.. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.Breast Cancer Res Treat1995; 36: 41–8.
7.
BombardieriE., PizzichettaM., Veronesi. CA 15.3 determination in patients with breast cancer: Clinical utility for the detection of distant metastases.Eur J Cancer1993; 29A: 144–6.
8.
Al-JarallahM.A., BehbehaniA.E., El-NassS.A.. Serum CA 15.3 patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.Eur J Surg Oncol1993; 19: 74–9.
9.
TondiniC., HayesD.F., GelmanR., HendersonI.C., KufeD.W.Comparison of CA 15.3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.Cancer Res1988; 48: 4107–12.
10.
RobertsonJ.F.R.Prospective confirmation of a biochemical index for measuring therapeutic efficacy in metastatic breast cancer in a multicentre study.The Breast1996; 5: 372–3.
11.
KallioniemiO.P., OksaH., AaranR.K., HietanenT., LehtinenM., KoivulaT.Serum CA 15.3 assay in the diagnosis and follow-up of breast cancer.Br J Cancer1988; 58: 213–5.
12.
ColomerR., RubalA., SalvadorL.Circulating tumour marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.Cancer1989; 64: 1674–81.
13.
WangD.Y., KnybaR.E., BulbrookR.D., MillisR.R., HaywardJ.L.Serum carcinoembryonic antigen in the diagnosis and prognosis of women with breast cancer.Eur J Cancer Clin Oncol1984; 20(1): 25–31.
14.
BerrutiA., TampelliniM., TortaM., BunivaT., GorzegnoG., DogliottiL.Prognostic value in predicting overall survival of two mucinous markers: CA 15.3 and CA 125 in breast cancer patients at first relapse of disease.Eur J Cancer30A; 1994 (14): 2082–4.
15.
CohenA.D., GopasJ., KarplusG., CohenY.CA 15.3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.Israel J Med Sciences1995; 31: 155–9.
16.
SundbladA.S., PellicerE.M., RicciL.Carcinoembryonic antigen expression in stage I and II breast cancer: its relationship with clinicopathologic factors.Human Pathol1996; 27: 297–301.
17.
PectasidesD., PavlidisN., GogouL.. Clinical value of CA 15.3, mucin-like carcinoma-associated antigen, tumour polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.Am J Clin Oncol1996; 19(5): 459–64.
18.
PykeC.M., MenezesG., PurdieD.M., JohnsonS., CowleyD.Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer.Australian & New Zealand J Surg1997; 67(65): 256–9.
19.
HorobinJ.M., BrowningM.C.K., McFarlaneN.P.. Potential use of tumor marker CA 15.3 in the staging and prognosis of patients with breast cancer.J R Coll Surg Edinb1991; 36: 219–21.
20.
WojtackiJ., Dziewulska-BokiniecA., KowalskiD.M., ZóltowskaA., CiesielskiD., SuszkoM.Serum CA 15.3 antigen - a prognostic factor in breast cancer patients.Przeglad Lekarski1996; 53(11): 788–92.
21.
O'HanlonD.M., KerinM.J., KentP., MaherD., GrimesH., GivenH.F.An evaluation of preoperative CA 15.3 measurement in primary breast carcinoma.Br J Cancer1995; 71: 1288–91.
22.
DixonA.R., JonrupI., JacksonL., ChanS.Y., BadleyR.A., BlarneyR.W.Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA and CA 15.3: fact or fiction?Disease Markers1991; 9: 167–74.
23.
RobertsonJ.F.R., PearsonD., PriceM.R., SelbyC., BlarneyR.W., HowellA.Objective measurement of therapeutic response in breast cancer using tumour markers.Br J Cancer1991; 64: 757–63.
24.
DixonA.R., JacksonL., ChanS.Y., BadleyR.A., BlarneyR.W.Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?Br J Cancer1993; 68: 181–5.
25.
NamerM., FumoleauP., RicolleauG.. Usefulness of tumour markers in bone metastases of breast cancer: prediction, diagnosis and prognosis therapeutic management (abstract).J Tumour Marker Oncol1991; 6: 56.
26.
GionM., MioneR., NascimbenO.. The tumour associated antigen CA 15.3 in primary breast cancer. Evaluation of 667 cases.Br J Cancer1991; 63: 809–13.
27.
BhatavdecarJ.M., PetelD.D., KareliaN.H.. Tumour markers in patients with advanced breast cancer as prognosticators: a preliminary study.Breast Cancer Res Treat1994; 30: 293–7.
28.
van DalenA.Pre-operative tumour marker levels in patients with breast cancer and their prognosis.Tumor Biol1990; 11: 189–95.
29.
EstebanJ.M., FelderB., ChulA., SimpsonJ.F., BattiforaH., ShivelyJ.E.Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.Cancer1994; 74: 1575–83.
30.
TampelliniM., BerrutiA., GerbinoA.. Relationship between CA 15.3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.Br J Cancer1997; 75: 698–702.
31.
AlbuquerqueK.V., PriceM.R., BadleyR.A.. Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival.Eur J Surg Oncol1995; 21: 504–9.
